Golimumab (Janssen Biotech Inc., Horsham, PA, USA) is a fully human anti-tumor necrosis factor alpha (TNFα) monoclonal antibody shown to be effective in patients with RA, ankylosing spondylitis, and PsA [6]. Here, TNF is linked to rheumatoid arthritis.